CompuGroup Medical expects revenues of EUR 1 billion in 2021 and invests in growth acceleration
DGAP-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Miscellaneous/Development of Sales
For the financial year 2021 very strong revenue growth of around 20 % is expected. This includes the two significant acquisitions in 2020, the acquisition of parts of the German and Spanish hospital information systems from Cerner, which was closed in July 2020, as well as the acquisition of US eMDs, Inc., which was announced on November 23, 2020. Effects for the Hospital Information Systems segment will occur mostly in Germany, and for the Ambulatory Information Systems business segment in the USA, with the US transaction still being subject to regulatory approvals. The strong revenue growth will also be driven by significantly higher organic growth of more than +5 % in the 2021 fiscal year. Adjusted EBITDA for the financial year 2021 is expected to remain at a similar level as in 2020. This corresponds to an EBITDA margin in a range of 20 to 23 %. The reduction in operating margin is attributable to planned additional investments in new technologies and distribution to realize numerous growth opportunities arising for CGM from the fast progressing digitization of the healthcare system. The Managing Directors and the Administrative Board want to use these opportunities to enable strong organic growth and an attractive EBITDA margin also in the years following. As planned, the full guidance for the financial year 2021 will be published in the standard format on February 4, 2021. CompuGroup Medical also confirms the guidance for the financial year 2020 which was raised in August. For the current year 2020, CompuGroup Medical is still expecting a revenue increase to a range of EUR 820 million to EUR 860 million and an adjusted EBITDA between EUR 205 million and EUR 220 million. Frank Gotthardt, founder and CEO, said, "The rapidly progressing digitization in the healthcare sector is a blessing for humanity. This offers us great business opportunities and at the same time obliges us to seize them for the benefit of our customers, our employees and our shareholders. I am excited about the great growth opportunities for CGM. And I am delighted with the enthusiasm, skill and drive of our team in tackling the enormous challenges that lie ahead. I could not wish for a better setting to hand the leadership of this successful team over to Dr. Dirk Wössner and his colleagues on the Executive Board at the end of the year." Explanations of the alternative financial ratios used (Alternative Performance Measures (APM)) can be found on the website of CompuGroup Medical SE & Co. KGaA in the annual report of CompuGroup Medical SE & Co. KGaA on pages 28 and 44 here.
About CompuGroup Medical SE & Co. KGaA Contact for media representatives:
07.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | CompuGroup Medical SE & Co. KGaA |
Maria Trost 21 | |
56070 Koblenz | |
Germany | |
Phone: | +49 (0)261 8000 7030 |
Fax: | +49 (0)261 8000 3200 |
E-mail: | investor@cgm.com |
Internet: | www.cgm.com |
ISIN: | DE000A288904 |
WKN: | A28890 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1153388 |
End of News | DGAP News Service |
|
1153388 07.12.2020